EUVIMEDEUVIMED entdecken
Open Access

Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter

Laura B Kozell, Amy J Eshleman, Tracy L Swanson, Shelley H Bloom, Katherine M Wolfrum, Jennifer L Schmachtenberg, Randall J Olson, Aaron Janowsky, Atheir I Abbas iD

The Journal of Pharmacology and Experimental Therapeutics · 2023

DOI: 10.1124/jpet.122.001454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023. Verfasst von Laura B Kozell und 8 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.…. Hauptthemen laut MEDLINE: Tryptamines, Hallucinogens. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied under medical guidance as potential treatments of psychiatric disorders. Characterizing the basic pharmacology of substituted tryptamines will aid in understanding differences in potential for harm or therapeutic use. Using human embryonic kidney cells stably expressing 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT2C receptors (5-HT1AR, 5-HT2AR, and 5HT2CR, respectively) or the serotonin transporter (SERT), we measured affinities, potencies and efficacies of 21 substituted tryptamines. With the exception of two 4-acetoxy compounds, substituted tryptamines exhibited affinities and potencies less than one micromolar at the 5-HT2AR, the primary target for psychedelic effects. In comparison, half or more exhibited low affinities/potencies at 5-HT2CR, 5-HT1AR, and SERT. Sorting by the ratio of 5-HT2A to 5-HT2C, 5-HT1A, or SERT affinity revealed chemical determinants of selectivity. We found that although 4-substituted compounds exhibited affinities that ranged across a factor of 100, they largely exhibited high selectivity for 5-HT2ARs versus 5-HT1ARs and 5-HT2CRs. 5-substituted compounds exhibited high affinities for 5-HT1ARs, low affinities for 5-HT2CRs, and a range of affinities for 5-HT2ARs, resulting in selectivity for 5-HT2ARs versus 5-HT2CRs but not versus 5-HT1ARs. Additionally, a number of psychedelics bound to SERT, with non-ring-substituted tryptamines most consistently exhibiting binding. Interestingly, substituted tryptamines and known psychedelic standards exhibited a broad range of efficacies, which were lower as a class at 5-HT2ARs compared with 5-HT2CRs and 5-HT1ARs. Conversely, coupling efficiency/amplification ratio was highest at 5-HT2ARs in comparison with 5-HT2CRs and 5-HT1ARs. SIGNIFICANCE STATEMENT: Synthetic substituted tryptamines represent both potential public health threats and potential treatments of psychiatric disorders. The substituted tryptamines tested differed in affinities, potencies, and efficacies at 5-hydroxytryptamine (5-HT)2A, 5-HT2C, and 5HT1A receptors and the serotonin transporter (SERT). Several compounds were highly selective for and coupled very efficiently downstream of 5-HT2A versus 5-HT1A and 5-HT2C receptors, and some bound SERT. This basic pharmacology of substituted tryptamines helps us understand the pharmacologic basis of their potential for harm and as therapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TryptaminesHallucinogensHumansSerotoninSerotonin Plasma Membrane Transport ProteinsReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2C

Substanzen

TryptaminesSerotoninSerotonin Plasma Membrane Transport ProteinsHallucinogensReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2C

Autor:innen und Institutionen

  • Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O…

ORCID-Profile: Atheir I Abbas

Förderung

  • NIDA NIH HHS

Zitieren

APA

Kozell, L. B., Eshleman, A. J., Swanson, T. L., Bloom, S. H., Wolfrum, K. M., Schmachtenberg, J. L., Olson, R. J., Janowsky, A., & Abbas, A. I. (2023). Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.122.001454

Vancouver

Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, et al. Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter. The Journal of Pharmacology and Experimental Therapeutics. 2023. doi:10.1124/jpet.122.001454

BibTeX
@article{Kozell2023,
  author = {Kozell, Laura B and Eshleman, Amy J and Swanson, Tracy L and Bloom, Shelley H and Wolfrum, Katherine M and Schmachtenberg, Jennifer L and Olson, Randall J and Janowsky, Aaron and Abbas, Atheir I},
  title = {Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2023},
  doi = {10.1124/jpet.122.001454}
}
Kostenlos starten →